BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 32591022)

  • 41. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
    BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations.
    Thompson MC; Fuller C; Hogg TL; Dalton J; Finkelstein D; Lau CC; Chintagumpala M; Adesina A; Ashley DM; Kellie SJ; Taylor MD; Curran T; Gajjar A; Gilbertson RJ
    J Clin Oncol; 2006 Apr; 24(12):1924-31. PubMed ID: 16567768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytogenetic prognostication within medulloblastoma subgroups.
    Shih DJ; Northcott PA; Remke M; Korshunov A; Ramaswamy V; Kool M; Luu B; Yao Y; Wang X; Dubuc AM; Garzia L; Peacock J; Mack SC; Wu X; Rolider A; Morrissy AS; Cavalli FM; Jones DT; Zitterbart K; Faria CC; Schüller U; Kren L; Kumabe T; Tominaga T; Shin Ra Y; Garami M; Hauser P; Chan JA; Robinson S; Bognár L; Klekner A; Saad AG; Liau LM; Albrecht S; Fontebasso A; Cinalli G; De Antonellis P; Zollo M; Cooper MK; Thompson RC; Bailey S; Lindsey JC; Di Rocco C; Massimi L; Michiels EM; Scherer SW; Phillips JJ; Gupta N; Fan X; Muraszko KM; Vibhakar R; Eberhart CG; Fouladi M; Lach B; Jung S; Wechsler-Reya RJ; Fèvre-Montange M; Jouvet A; Jabado N; Pollack IF; Weiss WA; Lee JY; Cho BK; Kim SK; Wang KC; Leonard JR; Rubin JB; de Torres C; Lavarino C; Mora J; Cho YJ; Tabori U; Olson JM; Gajjar A; Packer RJ; Rutkowski S; Pomeroy SL; French PJ; Kloosterhof NK; Kros JM; Van Meir EG; Clifford SC; Bourdeaut F; Delattre O; Doz FF; Hawkins CE; Malkin D; Grajkowska WA; Perek-Polnik M; Bouffet E; Rutka JT; Pfister SM; Taylor MD
    J Clin Oncol; 2014 Mar; 32(9):886-96. PubMed ID: 24493713
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New Approaches in Targeted Therapy for Medulloblastoma in Children.
    Maier H; Dalianis T; Kostopoulou ON
    Anticancer Res; 2021 Apr; 41(4):1715-1726. PubMed ID: 33813375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Signaling pathway and molecular subgroups of medulloblastoma.
    Li KK; Lau KM; Ng HK
    Int J Clin Exp Pathol; 2013; 6(7):1211-22. PubMed ID: 23826403
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach.
    Kaur K; Kakkar A; Kumar A; Mallick S; Julka PK; Gupta D; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2016 May; 26(3):334-43. PubMed ID: 26222673
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
    Liu X; Ding C; Tan W; Zhang A
    Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comprehensive analysis of differential expression profiles of mRNAs and lncRNAs and identification of a 14-lncRNA prognostic signature for patients with colon adenocarcinoma.
    Xing Y; Zhao Z; Zhu Y; Zhao L; Zhu A; Piao D
    Oncol Rep; 2018 May; 39(5):2365-2375. PubMed ID: 29565464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker.
    Korshunov A; Okonechnikov K; Sahm F; Ryzhova M; Stichel D; Schrimpf D; Ghasemi DR; Pajtler KW; Antonelli M; Donofrio V; Mastronuzzi A; Rossi S; Camassei FD; Buccoliero AM; Haberler C; Slavc I; Dahiya S; Casalini B; Sievers P; Meyer J; Kumirova E; Zheludkova O; Golanov A; Jones DTW; Pfister SM; Kool M; von Deimling A
    Acta Neuropathol; 2020 Mar; 139(3):583-596. PubMed ID: 31781912
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinicomorphological and molecular analysis of medulloblastoma and association with survival: A single tertiary care center experience.
    Badiger S; Gudipati A; Uppin M; Konatam ML; Yeramneni VK; Bhattacharjee S; Saradhi MV; Patnaik S; Irukulla M
    J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S592-S602. PubMed ID: 38384024
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinically unfavorable transcriptome subtypes of non-WNT/non-SHH medulloblastomas are associated with a predominance in proliferating and progenitor-like cell subpopulations.
    Okonechnikov K; Schrimpf D; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M; Korshunov A
    Acta Neuropathol; 2024 Jun; 147(1):95. PubMed ID: 38847845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preoperative Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio are Associated with the Prognosis of Group 3 and Group 4 Medulloblastoma.
    Li K; Duan WC; Zhao HB; Wang L; Wang WW; Zhan YB; Sun T; Zhang FJ; Yu B; Bai YH; Wang YM; Ji YC; Zhou JQ; Liu XZ; Zhang ZF; Zhang ZY
    Sci Rep; 2019 Sep; 9(1):13239. PubMed ID: 31519974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epigenetic regulation in medulloblastoma pathogenesis revealed by genetically engineered mouse models.
    Shiraishi R; Kawauchi D
    Cancer Sci; 2021 Aug; 112(8):2948-2957. PubMed ID: 34050694
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
    Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
    J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Integrated analysis of miRNA and mRNA expression in childhood medulloblastoma compared with neural stem cells.
    Genovesi LA; Carter KW; Gottardo NG; Giles KM; Dallas PB
    PLoS One; 2011; 6(9):e23935. PubMed ID: 21931624
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Two machine learning methods identify a metastasis-related prognostic model that predicts overall survival in medulloblastoma patients.
    Chen K; Huang B; Yan S; Xu S; Li K; Zhang K; Wang Q; Zhuang Z; Wei L; Zhang Y; Liu M; Lian H; Zhong C
    Aging (Albany NY); 2020 Nov; 12(21):21481-21503. PubMed ID: 33159021
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehensive analysis of differentially expressed profiles of lncRNAs, mRNAs, and miRNAs in laryngeal squamous cell carcinoma in order to construct a ceRNA network and identify potential biomarkers.
    Kong X; Qi J; Yan Y; Chen L; Zhao Y; Fang Z; Fan J; Liu M; Liu Y
    J Cell Biochem; 2019 Oct; 120(10):17963-17974. PubMed ID: 31127661
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tumor-associated macrophages in SHH subgroup of medulloblastomas.
    Margol AS; Robison NJ; Gnanachandran J; Hung LT; Kennedy RJ; Vali M; Dhall G; Finlay JL; Erdreich-Epstein A; Krieger MD; Drissi R; Fouladi M; Gilles FH; Judkins AR; Sposto R; Asgharzadeh S
    Clin Cancer Res; 2015 Mar; 21(6):1457-65. PubMed ID: 25344580
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LncRNA CDKN2BAS rs2157719 genetic variant contributes to medulloblastoma predisposition.
    Chen YD; Zhang N; Qiu XG; Yuan J; Yang M
    J Gene Med; 2018 Jan; 20(1):. PubMed ID: 29314442
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression profiling of long noncoding RNAs associated with vasculogenic mimicry in osteosarcoma.
    Ren K; Ni Y; Li X; Wang C; Chang Q; Li Y; Gao Z; Wu S; Shi X; Song J; Yao N; Zhou J
    J Cell Biochem; 2019 Aug; 120(8):12473-12488. PubMed ID: 30825232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.